CTLA4 and neoplasm: Dual blockade of two immune checkpoints enhances function of TILs resulting in a significant tumor rejection, as demonstrated by the combination of anti-CTLA-4 with anti-PD-1/PD-L1.Anti-PD-1 and anti-TIGT dual therapy significantly improved survival compared to control and monotherapy in a murine glioblastoma (GBM) model.